Minimally invasive metabolic testing for malignant hyperthermia susceptibility: a systematic review of the methodology and results

Bibliography

• Denborough MA, Forster JF, Lovell RR, Anaesthetic deaths in a family. Br J Anaesth 1962;34:395-6
   PubMed Web of Science ®Google Scholar
• Hartung E, Anetseder M, Olthoff D, Regional distribution of predisposition to maligant hyperthermia in Germany: tate in 1997. Anasthesiol Intensivmed Notfallmed Schmerzther 1998;33(4):238-43
   PubMed Web of Science ®Google Scholar
• DGAI. Maligne Hyperthermie. Anästh Intensivmed 2008;49:483-88
   Google Scholar
• Mickelson JR, Louis CF. Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Physiol Rev 1996;76(2):537-92
   PubMed Web of Science ®Google Scholar
• O'Sullivan GH, McIntosh JM, Heffron JJ. Abnormal uptake and release of Ca2+ ions from human malignant hyperthermia-susceptible sarcoplasmic reticulum. Biochem Pharmacol 2001;61(12):1479-85
   PubMed Web of Science ®Google Scholar
• Dirksen RT, Avila G. Distinct effects on Ca2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys J 2004;87(5):3193-204
   PubMed Web of Science ®Google Scholar
• Paul-Pletzer K, Yamamoto T, Bhat MB, Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 2002;277(38):34918-23
   PubMed Web of Science ®Google Scholar
• Fruen BR, Mickelson JR, Louis CF. Dantrolene inhibition of sarcoplasmic reticulum Ca2 + release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem 1997;272(43):26965-71
   PubMed Web of Science ®Google Scholar
• The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984;56(11):1267-71
   PubMed Web of Science ®Google Scholar
• Rosenberg H, Antognini JF, Muldoon S. Testing for malignant hyperthermia. Anesthesiology 2002;96(1):232-7
   PubMed Web of Science ®Google Scholar
• McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000;15(5):410-7
   PubMed Web of Science ®Google Scholar
• Phillips MS, Fujii J, Khanna VK, The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics 1996;34(1):24-41
   PubMed Web of Science ®Google Scholar
• Gillard EF, Otsu K, Fujii J, Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics 1992;13(4):1247-54
   PubMed Web of Science ®Google Scholar
• Weiss RG, O'Connell KM, Flucher BE, Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am J Physiol Cell Physiol 2004;287(4):C1094-102
   PubMed Web of Science ®Google Scholar
• Mathews KD, Moore SA. Multiminicore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 mutations: one disease with many faces? Arch Neurol 2004;61(1):27-9
   PubMed Web of Science ®Google Scholar
• Migita T, Mukaida K, Hamada H, Functional analysis of ryanodine receptor Type 1 p.R2508C mutation in exon 47. J Anesth 2009;23(3):341-6
   PubMed Web of Science ®Google Scholar
• Robinson RL, Anetseder MJ, Brancadoro V, Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003;11(4):342-8
   PubMed Web of Science ®Google Scholar
• Sei Y, Sambuughin NN, Davis EJ, Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004;101(4):824-30
   PubMed Web of Science ®Google Scholar
• Bendahan D, Kozak-Ribbens G, Rodet L, 31Phosphorus magnetic resonance spectroscopy characterization of muscular metabolic anomalies in patients with malignant hyperthermia: application to diagnosis. Anesthesiology 1998;88(1):96-107
   PubMed Web of Science ®Google Scholar
• Sei Y, Brandom BW, Bina S, Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. Anesthesiology 2002;97(5):1052-8
   PubMed Web of Science ®Google Scholar
• Muller M. Science, medicine, and the future: Microdialysis. BMJ 2002;324(7337):588-91
   PubMed Web of Science ®Google Scholar
• Benveniste H, Huttemeier PC. Microdialysis-theory and application. Prog Neurobiol 1990;35(3):195-215
   PubMed Web of Science ®Google Scholar
• Trinity Biotec. Lactate (Procedure No. 735-10) Operation instruction. 1 January 1994; Wicklow, Ireland
   Google Scholar
• Schuster F, Scholl H, Hager M, The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs. Anesth Analg 2006;102(2):468-72
   PubMed Web of Science ®Google Scholar
• Bina S, Cowan G, Karaian J, Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis. Anesthesiology 2006;104(1):90-100
   PubMed Web of Science ®Google Scholar
• Bina S, Muldoon S, Bunger R. Effects of ryanodine on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis. Eur J Anaesthesiol 2008;25(1):48-57
   PubMed Web of Science ®Google Scholar
• Bundesinstitut für Arzneimittel und Medizinprodukte. 61. 4 January 2002
   Google Scholar
• Schuster F, Metterlein T, Negele S, Intramuscular injection of sevoflurane detects malignant hyperthermia predisposition in susceptible pigs. Anesthesiology 2007;107(4):616-20
   PubMed Web of Science ®Google Scholar
• Metterlein T, Schuster F, Horbaschek H, Roewer AM. Volatile anesthetics induce different contractures in muscle bundles of MH susceptible individuals. Annual Meeting of the European MH Group. 1 May 2008. Lund, Sweden
   Google Scholar
• Anetseder M, Hager M, Muller CR, Roewer N. Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. Lancet 2002;359(9317):1579-80
   PubMed Web of Science ®Google Scholar
• Metterlein T, Schuster F, Kranke P, Intramusclar injection of malignant hyperthermia trigger agents induces hypermetabolism in susceptible and non-susceptible individuals. Eur J Anaesthesiol 2010;27(1):77-82
   PubMed Web of Science ®Google Scholar
• Schuster F, Hager M, Metterlein T, In-vivo diagnosis of malignant hyperthermia susceptibility: a microdialysis study. Anaesthesist 2008;57(8):767-74
   PubMed Web of Science ®Google Scholar
• Schuster F, Gardill A, Metterlein T, A minimally invasive metabolic test with intramuscular injection of halothane 5 and 6 vol% to detect probands at risk for malignant hyperthermia. Anaesthesia 2007;62(9):882-7
   PubMed Web of Science ®Google Scholar
• Schuster F, Metterlein T, Negele S, An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study. Anesth Analg 2008;107(3):909-14
   PubMed Web of Science ®Google Scholar
• Monsieurs KG, Van Broeckhoven C, Martin JJ, Gly341Arg mutation indicating malignant hyperthermia susceptibility: specific cause of chronically elevated serum creatine kinase activity. J Neurol Sci 1998;154(1):62-5
   PubMed Web of Science ®Google Scholar
• Smith I. Total intravenous anaesthesia: is it worth the cost? CNS Drugs 2003;17(9):609-19
   PubMed Web of Science ®Google Scholar
• De Hert SG. Cardioprotection with volatile anesthetics: clinical relevance. Curr Opin Anaesthesiol 2004;17(1):57-62
   PubMedGoogle Scholar